中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
Report Reversal of liver failure using a bioartificial liver device implanted with clinical-grade human-induced hepatocytes

文献类型：期刊论文

作者Wang, Yifan3,4,5; Zheng, Qiang3; Sun, Zhen6; Wang, Chenhua1; Cen, Jin1; Zhang, Xinjie3; Jin, Yan3; Wu, Baihua1; Yan, Tingting3; Wang, Ziyuan3
刊名CELL STEM CELL
出版日期2023-05-04
卷号30期号:5页码:617-+
ISSN号1934-5909
DOI10.1016/j.stem.2023.03.013
通讯作者Zhang, Ludi(zhangludi@sibcb.ac.cn) ; Hui, Lijian(ljhui@sibcb.ac.cn) ; Cai, Xiujun(srrsh_cxj@zju.edu.cn)
英文摘要Liver resection is the first-line treatment for primary liver cancers, providing the potential for a cure. However, concerns about post-hepatectomy liver failure (PHLF), a leading cause of death following extended liver resection, have restricted the population of eligible patients. Here, we engineered a clinical-grade bioartificial liver (BAL) device employing human-induced hepatocytes (hiHeps) manufactured under GMP conditions. In a porcine PHLF model, the hiHep-BAL treatment showed a remarkable survival benefit. On top of the support-ive function, hiHep-BAL treatment restored functions, specifically ammonia detoxification, of the remnant liver and facilitated liver regeneration. Notably, an investigator-initiated study in seven patients with extended liver resection demonstrated that hiHep-BAL treatment was well tolerated and associated with improved liver function and liver regeneration, meeting the primary outcome of safety and feasibility. These encouraging re-sults warrant further testing of hiHep-BAL for PHLF, the success of which would broaden the population of patients eligible for liver resection.
WOS关键词PORCINE MODEL ; GENE-EXPRESSION ; IN-VITRO ; HEPATECTOMY ; CELLS ; FIBROBLASTS ; SENESCENCE ; ALPPS ; TRIAL
资助项目National Key Research and Development Project[2020YFA0112503] ; National Key Research and Development Project[2020YFC2002803] ; Strategic Priority Research Program of the Chinese Academy of Sciences (CAS)[XDA16020201] ; National Natural Science Foundation of China (NSFC)[32221002] ; National Natural Science Foundation of China (NSFC)[32070797] ; Shanghai Municipal Commission for Science and Technology[22JC1403001] ; Key Research and Development Project of Zhejiang Province[2018C03083] ; Key Research and Development Project of Zhejiang Province[2020C03122] ; Youth Innovation Promotion Association CAS ; SA-SIBS Scholarship Program
WOS研究方向Cell Biology
语种英语
出版者CELL PRESS
WOS记录号WOS:001006296100001
源URL[http://119.78.100.183/handle/2S10ELR8/306305]  
专题中国科学院上海药物研究所
通讯作者Zhang, Ludi; Hui, Lijian; Cai, Xiujun
作者单位1.Univ Chinese Acad Sci, Chinese Acad Sci, Shanghai Inst Biochem & Cell Biol, CAS Ctr Excellence Mol Cell Sci,State Key Lab Cel, Shanghai 200031, Peoples R China
2.Chinese Acad Sci, Shanghai Inst Materia Med, Shanghai 201203, Peoples R China
3.Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Gen Surg, Hangzhou 310016, Peoples R China
4.Zhejiang Minimal Invas Diag & Treatment Technol Re, Hangzhou 310016, Peoples R China
5.Key Lab Laparoscop Technol Zhejiang Prov, Hangzhou 310016, Peoples R China
6.ShanghaiTech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China
7.Univ Chinese Acad Sci, Hangzhou Inst Adv Study, Sch Life Sci, Hangzhou 310024, Peoples R China
推荐引用方式
GB/T 7714		 Wang, Yifan,Zheng, Qiang,Sun, Zhen,et al. Report Reversal of liver failure using a bioartificial liver device implanted with clinical-grade human-induced hepatocytes[J]. CELL STEM CELL,2023,30(5):617-+.
APA Wang, Yifan.,Zheng, Qiang.,Sun, Zhen.,Wang, Chenhua.,Cen, Jin.,...&Cai, Xiujun.(2023).Report Reversal of liver failure using a bioartificial liver device implanted with clinical-grade human-induced hepatocytes.CELL STEM CELL,30(5),617-+.
MLA Wang, Yifan,et al."Report Reversal of liver failure using a bioartificial liver device implanted with clinical-grade human-induced hepatocytes".CELL STEM CELL 30.5(2023):617-+.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。